{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015839","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.064515+00:00","generated_at":"2026-05-29T23:05:24.394518+00:00","sec_items":["5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"NeuroBo to rename to MetaVia Nov 29; ticker changes to MTVA","bullets":["NeuroBo Pharmaceuticals changes legal name to MetaVia Inc., effective Nov 29, 2024.","Nasdaq ticker symbol changes from NRBO to MTVA on the same date.","No shareholder vote required; CUSIP and transfer agent unchanged.","Company expects Phase 2a data for DA-1241 (MASH) in Dec 2024 and Phase 1 obesity data in Q1 2025.","June financing of up to $70M ($20M upfront, $50M warrants) provides funding runway."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015839","json":"https://secwatch.observer/filing/0001558370-24-015839.json","markdown":"https://secwatch.observer/filing/0001558370-24-015839.md","text":"https://secwatch.observer/filing/0001558370-24-015839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024015839/0001558370-24-015839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024015839/nrbo-20241115x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:05:24.394518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18caa675585d1e9f2cca6c4f6022d17b2a19a247","claim":"MetaVia Inc.: Amended and restated bylaws to reflect the name change and other technical changes (effective 2024-11-29).","evidence_excerpt":"the Board of Directors of the Company approved an amendment and restatement (the “Fourth Amended and Restated Bylaws”) of the Company’s Third Amended and Restated Bylaws, effective as of November 29, 2024. The Fourth Amended and Restated Bylaws reflect the Name Change, as well as certain other technical changes.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024015839/0001558370-24-015839-index.htm","confidence":1.0,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-11-29"}],"fact_type":"governance_change"},{"claim_id":"4c409ab0059bc1fd7215f013ec3737760ea33c5e","claim":"MetaVia Inc.: Changed legal name from NeuroBo Pharmaceuticals, Inc. to MetaVia Inc (effective 2024-11-29).","evidence_excerpt":"On November 15, 2024, NeuroBo Pharmaceuticals, Inc. (the “Company” or the “Registrant”) filed a Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation (“Certificate of Amendment”) with the Secretary of State of the State of Delaware to change the legal name of the Company from “NeuroBo Pharmaceuticals, Inc.” to “MetaVia Inc.,” effective as of November 29, 2024.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024015839/0001558370-24-015839-index.htm","confidence":1.0,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-11-29"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}